Intellia Therapeutics Inc (NTLA NASDAQ) stock market data APIs
$13.576
-1.28(-9.4%)
as of November 5, 2025
Try our APIs with
free plan!
Intellia Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
13.576
Open
12.298
High
13.7257
Low
12.0548
52 wk Range
5.9-28.25
Market Cap
1 310 M
Shares Outstanding
107 M
Revenue
52 857 K
EPS
0
Beta
2.11
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Intellia Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intellia Therapeutics Inc data using free add-ons & libraries
Get Intellia Therapeutics Inc Fundamental Data
Intellia Therapeutics Inc Fundamental data includes:
- Net Revenue: 52 857 K
- EBITDA: -501 873 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -1.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intellia Therapeutics Inc News
New
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
Vertex Pharmaceuticals Incorporated’s VRTX third-quarter 2025 results were strong as it beat estimates for both earnings and sales. The company’s total revenues of $3.08 billion rose 11% year ov...
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks Consensus Estimate of $4.55. Earnings rose around 10% year over year. Tot...
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome Therapeutics AXSM incurred a loss of 94 cents per share in the third quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of $1.34 per...
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics TGTX reported earnings of $2.43 per share for the third quarter of 2025, which significantly beat the Zacks Consensus Estimate of 24 cents. The company had reported earnings of 2 cents...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
